AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 121 min read$REGN

Guarini Kathryn sold $320K of REGN

Guarini Kathryn sold 400 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $800.00 ($0.32M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Guarini Kathryn
Published Aug 12, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$REGN
Neutral
medium confidence
Mentioned
$REGN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNNeutralLow
01

Why it matters

The only new fact is the reported open-market sale of 400 shares at $800/share on Aug. 10, with a 10b5-1 pre-arranged plan confirmed.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and modest transaction size suggest limited incremental impact.

03

What to watch

The filing does not disclose reasons for the sale, and the post-transaction holdings (603 shares) are small relative to typical institutional float, limiting signal strength.

Relevance 3/10Novelty 3/10Timing: filed after-hours on Aug. 12, covering a sale dated Aug. 10

Background

The article is an SEC Form 4 insider transaction disclosure for Regeneron Pharmaceuticals, Inc.

Company-level read

Ticker impact

$REGNNeutralMedium confidence
Context

Regeneron director Kathryn Guarini sold 400 shares in an open-market transaction at $800/share under a 10b5-1 plan, filed Aug. 12.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

Form 4 reports the sale size and price ($320,000 total) and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

Sector

Minimal. Insider transaction in a single biotech name does not materially reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations, so any negative read-through may be overstated.

Key entities

  • issuer
    REGN

    Regeneron Pharmaceuticals, Inc., the company whose director insider sale is disclosed.

  • insider
    Kathryn Guarini

    Director of Regeneron who sold 400 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

REGN insider trading history →

Related articles

SEP 2
$REGNMedAI 8/10

Regeneron Pharmaceuticals stock hits 52-week high at $847.60

Regeneron Pharmaceuticals (REGN) hit a 52-week high of $847.60, up 50.05% over the past year. The stock trades at $847.19, 32% below its InvestingPro Fair Value of $1,118. Q2 2026 earnings were $14.29 per share, with revenue of $4.29 billion, up 17% YoY. Analysts raised price targets, with BofA Securities at $891 and Bernstein SocGen at $756.

investing.com2 min
AUG 31
$REGNMedAI 8/10

Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru (garetosmab-grts), a new rare disease therapy for fibrodysplasia ossificans progressiva. The drug can be infused at home and showed strong lesion-reduction results. Analysts discuss its impact on Regeneron's investment case, with projections of $19.4B revenue and $6.0B earnings by 2029. Pasatru adds to Regeneron's portfolio but EYLEA's performance remains a key focus.

simplywall.st3 min
AUG 29
$REGNMedAI 9/10

Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru to treat adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 trial results. The approval adds a new rare disease therapy to Regeneron's portfolio, potentially diversifying revenue streams. REGN has a market cap of US$80.7b and focuses on immunology and genetic medicine.

yahoo.com2 min
AUG 27
$REGNMedAI 8/10

Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?

The FDA approved Regeneron's (REGN) Pasatru for fibrodysplasia ossificans progressiva, a rare disease. The drug showed a 94% reduction in new bone lesions in a Phase 3 trial. Regeneron's Q2 revenue was $4.29B, up 17%, with strong sales from Dupixent and Eylea HD. Pasatru's market potential is limited due to the disease's rarity, but it validates Regeneron's research platform.

finance.yahoo.com2 min
AUG 26
$REGNMedAI 8/10

Regeneron terminates mAb eye therapy trial amid safety concerns

Regeneron halted its Phase I/IIa TITAN trial for mAb therapy REGN7041 due to safety concerns, according to a filing and company statement. The trial, targeting noninfectious uveitis, enrolled only one patient. Regeneron cited an unfavorable risk-benefit assessment and noted the cause of the safety event remains unidentified.

bioxconomy.com2 min
AUG 23
$REGNHighAI 9/10

Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru, a first-in-class treatment for fibrodysplasia ossificans progressiva. The approval is based on positive Phase 3 trial results. Analysts discuss how this new drug may impact Regeneron's investment narrative, alongside existing key products like EYLEA HD and Dupixent. The company projects $19.4B revenue and $6.0B earnings by 2029, with optimistic analysts suggesting higher figures.

simplywall.st2 min